中文名称: | Begacestat | ||||
---|---|---|---|---|---|
英文名称: | Begacestat | ||||
别名: | (S)-5-氯-N-(4,4,4-三氟-1-羟基-3-(三氟甲基)-2-丁基)噻吩-2-磺酰胺;脱乙酰头孢匹林钠盐;GSI-953 国华试剂 5-Chloro-N-((1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl)thiophene-2-sulfonamide | ||||
CAS No: | 769169-27-9 | 分子式: | C9H8ClF6NO3S2 | 分子量: | 391.74 |
CAS No: | 769169-27-9 | ||||
分子式: | C9H8ClF6NO3S2 | ||||
分子量: | 391.74 |
基本信息
产品编号: |
B11702 |
||||
产品名称: |
Begacestat |
||||
CAS: |
769169-27-9 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
分子量 |
391.74 |
-20℃ |
1个月 |
||
化学名: |
5-Chloro-N-((1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl)thiophene-2-sulfonamide |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
50 mg/mL (127.64mM; Need ultrasonic) |
|||
Ethanol |
|
||||
Water |
|
||||
体内(现配现用): |
1.请依序添加每种溶剂:10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility: ≥ 2.5 mg/mL (6.38mM); Clear solution |
||||
此⽅案可获得 ≥ 2.5 mg/mL (6.38mM,饱和度未知) 的澄清溶液。 以 1mL ⼯作液为例,取 100μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中,混合均匀;向上述体系中加⼊ 50μL Tween-80,混合均匀;然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。 |
|||||
2.请依序添加每种溶剂: 10% DMSO→90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.38mM); Clear solution |
|||||
此⽅案可获得 ≥ 2.5 mg/mL (6.38mM,饱和度未知) 的澄清溶液。以 1mL ⼯作液为例,取 100μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中,混合均 匀 |
|||||
3.请依序添加每种溶剂: 10% DMSO→90% corn oil Solubility: ≥ 2.5 mg/mL (6.38mM); Clear solution |
|||||
此⽅案可获得 ≥ 2.5 mg/mL (6.38mM,饱和度未知) 的澄清溶液,此⽅案不适⽤于实验周期在半个⽉以上的实验。 以 1mL ⼯作液为例,取 100μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900μL ⽟⽶油中,混合均匀。 |
|||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.5527mL |
12.7636mL |
25.5271mL |
5mM |
0.5105mL |
2.5527mL |
5.1054mL |
10mM |
0.2553mL |
1.2764mL |
2.5527mL |
生物活性
产品描述 |
一种淀粉样前体蛋白 γ 分泌酶 (gamma-secretase) 的选择性噻吩磺酰胺抑制剂 (IC50Aβ40=15nM),。 |
|
靶点 |
IC50: 15nM (Aβ40) |
|
体内研究 |
Begacestat (5 mg/kg, p.o. in mice) treatment for 4 h significantly reduces the Aβ40 and Aβ42 in brain (37% lowering of brain A β40 and 25% lowering of Aβ40 observed). Begacestat (GSI-953: 0, 2.5, 5, or 10 mg/kg, oral gavage, 3 h) results in a dose-dependent reversal of contextual fear conditioning deficits when compound is orally administered 3 h before training. Significant deficits are observed after treatment with 2.5 mg/kg Begacestat, and there is some reversal of this at 5 mg/kg and full reversal at 10 mg/kg compared with vehicle-dosed Tg2576 mice. A dosage-related trend of slightly lower percentages of SP CD4+ cells in males at all dosages (SP CD4+ cells=~11% in controls compared with ~7% to ~9% in Begacestat-dosed animals) and females at 2000 mg/kg/day (SP CD4+ cells=~10% in controls compared with ~8% in Begacestat-dosed animals) is observed.
|
|
Animal Model: |
Tg2576 mice |
|
Dosage: |
0, 2.5, 5, or 10 mg/kg |
|
Administration: |
Oral gavage for two consecutive days |
|
Result: |
Resulted in a dose-dependent reversal of contextual fear conditioning deficits when compound is orally administered 3 h before training. |
|
|
||
Animal Model: |
Sprague-Dawley rats |
|
Dosage: |
0, 200, 600, or 2000 mg/kg/day for 10 (5 males/group and 5 females at 600 mg/kg/day) or 28 (10/sex/group) consecutive days |
|
Administration: |
P.O. for 10 (5 males/group and 5 females at 600 mg/kg/day) or 28 (10/sex/group) consecutive days. |
|
Result: |
A dosage-related trend of slightly lower percentages of SP CD4+ cells in males at all dosages and females at 2000 mg/kg/day was observed. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )